Lead Sponsor

Xinqiao Hospital of Chongqing

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•1. Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent.
•2. the advanced malignant tumors (solid tumors of the non-small-cell lung carcinoma, stomach, breast, urinary system, etc.) were diagnosed by histopathology.
•3. the stage IV according to the eighth edition of IASLC.
•4. PS 0-2, the expected survival \> 3 months.
•5. the age of 18-75 years.
•6. no contraindication to treatment with immune checkpoint inhibitors.

•1. the patients' compliance was poor, which violated the rules of the trial;
•2. the patients with severe dysfunction of vital organs (heart, liver and kidney) ;
•3. the patients with other malignant tumors;
•4. the researchers considered that the patients should not participate in other conditions of the trial.

Related studies

NCT07515118 · Infertility, Ovarian Stimulation, and more

NCT07528066 · Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, and more

NCT07087418 · Digestive Diseases, Radiology, and more

NCT06426992 · Liver Malignant Tumors

NCT07075679 · Breast Cancer Screening, Artificial Intelligence (AI), and more

A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies